Dr. Aloïse Mabondzo | drug design | Best Researcher Award

Dr. Aloïse Mabondzo | drug design | Best Researcher Award

Doctorate at CEA, France

Professional Profiles

Google Scholar

Scopus

Orcid

🎓 Educational Background

Dr. Aloïse Mabondzo, has a distinguished academic foundation. He earned his Master’s degree in Molecular and Cellular Biology from the University of Strasbourg, France (1986-1989). Driven by a passion for cutting-edge research, he pursued a PhD in Virology and Immunology at the prestigious Pierre and Marie Curie University, France (1989-1993). His doctoral work focused on Active Immunotherapy using bispecific antibodies against HIV, a testament to his early commitment to tackling global health challenges.

🧪 Professional Positions

Dr. Mabondzo’s illustrious career began with a Post-doctoral Research Fellowship (1993-1997) at the CEA Neurovirology Department, where he made significant contributions to the field of neurovirology. In 1998, he joined the CEA Medicine and Healthcare Technologies Department, where he has served as Research Director and Head of the Neurovascular Unit Research and Therapeutic Innovation Laboratory. His leadership in these roles has driven breakthroughs in neurovascular research. Since 2019, Dr. Mabondzo has also been the Co-founder and Research Director of Ceres Brain Therapeutics, a startup dedicated to pioneering therapeutic innovations.

👩‍🏫 Mentoring and Supervision

Dr. Mabondzo has a proven track record as a mentor and supervisor. Over his career, he has supervised 16 PhD candidates (10 past, 6 current), 7 Postdoctoral Fellows (4 past, 3 current), and several other researchers, including 2 Research Assistants, 2 Engineers, and 2 Technicians. His mentorship has nurtured the next generation of scientists, fostering innovation and collaboration.

Publications Top Noted📄 

Dodecyl creatine ester therapy: from promise to reality

Authors: Mabondzo, A.; van de Kamp, J.; Mercimek-Andrews, S.

Journal: Cellular and Molecular Life Sciences

Year: 2024

A Fab of trastuzumab to treat HER2 overexpressing breast cancer brain metastases

Authors: Angeli, E.; Paris, J.; Le Tilly, O.; Paintaud, G.; Bousquet, G.

Journal: Experimental Hematology and Oncology

Year: 2024

Impaired brain glucose metabolism as a biomarker for evaluation of dodecyl creatine ester in creatine transporter deficiency: Insights from patient brain-derived organoids and in vivo [18F]FDG PET imaging in a mouse model

Authors: Disdier, C.; Soyer, A.; Broca-Brisson, L.; Tournier, N.; Mabondzo, A.

Journal: Neurobiology of Disease

Year: 2024

Targeting the Multiple Complex Processes of Hypoxia-Ischemia to Achieve Neuroprotection

Authors: Maïza, A.; Hamoudi, R.; Mabondzo, A.

Journal: International Journal of Molecular Sciences

Year: 2024

Epigenetic alterations in creatine transporter deficiency: a new marker for dodecyl creatine ester therapeutic efficacy monitoring

Authors: Broca-Brisson, L.; Disdier, C.; Harati, R.; Hamoudi, R.; Mabondzo, A.

Journal: Frontiers in Neuroscience

Year: 2024

Dr. Cesira Giordano, Medicinal Chemistry, Women Researcher Award

Dr. Cesira Giordano, Medicinal Chemistry, Women Researcher Award

Doctorate at Azienda Opedaliero-Universitaria Pisana, Italy

Professional Profiles

Scopus

Orcid

🎓 Education and Academic Background

Cesira Giordano, born on January 28, 1987, holds a Master’s Degree in Molecular Biology, with a specialization in Microbiology and Virology. She furthered her expertise by completing a 2nd level Master’s in OMIC Data Analysis, reflecting her commitment to integrating cutting-edge technology into her field.

🧑‍🔬 Professional Qualifications and Current Role

Since October 2019, Cesira has held a permanent position as a Biologist Manager at the Hospital Microbiology Department of Azienda Ospedaliero-Universitaria Pisana (AOUP) in Pisa. As a Clinical Microbiologist, she is responsible for key microbiological analyses, including regional control measures in line with Tuscany’s Decree No. 16286 of 2017. Cesira’s work ensures public health laboratories maintain their high standards, particularly through her role as the Single EQA (External Quality Assessment) contact person for SD Hospital Microbiology at AOUP.

🏆 Leadership in Public Health and Tender Commissions

Cesira has been actively involved in public health laboratory management, serving as a Tender Commissioner for various public health tenders in 2023 and 2024. Her roles include:

  • June 2024: Tender Commissioner for AOUP ESTAR, overseeing consumables and accessories for public health laboratories.
  • September 2023: Tender Commissioner for AOUP, focusing on microbiological identifications and antibiotic testing (Antibiograms).
  • July 2023–Ongoing: AOUP Contact Person for the Tuscany Region regarding communications about Listeria monocytogenes.

🔬 Research Contributions and Innovations

Cesira’s research focuses on the development and application of innovative microbiological technologies. Between 2018 and 2019, she was awarded a research grant to develop Fourier Transform Infrared Spectroscopy (FTIR) technology for identifying bacteria and yeast. This work, conducted in collaboration with the University of Pisa, has laid the groundwork for bacterial typing and investigating antibiotic resistance.

Her other research highlights include:

2018: Development of rapid antibiogram protocols for multi-organ donor samples, under the supervision of Dr. Simona Barnini.

2017: Analysis of the genomes of Klebsiella pneumoniae using Next Generation Sequencing (NGS) techniques. This project aimed at identifying new genes responsible for antibiotic resistance, carried out under the leadership of Dr. Simona Barnini.

🌍 International Research and Collaboration

In 2016, Cesira expanded her research experience internationally, spending time at the University Medical Center Groningen (UMCG), Netherlands. There, she worked on whole genome sequencing of multi-resistant Klebsiella pneumoniae strains, contributing to the understanding of antibiotic resistance mechanisms under the guidance of Prof. Dr. Alexander Friedrich, Dr. Erik Bathoorn, and Dr. John Rossen.

🧪 Pioneering Work in Microbiological Diagnostics

Cesira has made significant strides in rapid diagnostic methodologies. In 2016, she played a crucial role in developing rapid molecular and phenotypic antibiograms aimed at diagnosing sepsis swiftly. The protocols she helped develop reduced diagnostic time to as little as 3-6 hours after blood culture positivity, using advanced techniques like MALDI TOF MS. These advancements have greatly improved clinical response times in critical cases, saving lives.

Publications Top Noted📚

Frequency of cefiderocol heteroresistance among patients treated with cefiderocol for carbapenem-resistant Acinetobacter baumannii infections

Authors: Shields, R.K., Dorazio, A.J., Tiseo, G., Doi, Y., Falcone, M.

Journal: JAC-Antimicrobial Resistance

Year: 2024

Glycine restores the sensitivity to antibiotics in multidrug-resistant bacteria

Authors: Giordano, C., Barnini, S.

Journal: Microbiology Spectrum

Year: 2024

Clinical Features and Outcomes of Infections Caused by Metallo-β-Lactamase-Producing Enterobacterales: A 3-Year Prospective Study from an Endemic Area

Authors: Falcone, M., Giordano, C., Leonildi, A., Barnini, S., Tiseo, G.

Journal: Clinical Infectious Diseases

Year: 2024

Real-world experience with meropenem/vaborbactam for the treatment of infections caused by ESBL-producing Enterobacterales and carbapenem-resistant Klebsiella pneumoniae

Authors: Tiseo, G., Galfo, V., Riccardi, N., Barnini, S., Falcone, M.

Journal: European Journal of Clinical Microbiology and Infectious Diseases

Year: 2024

Activity of novel β-lactam/β-lactamase inhibitor combinations against serine carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa

Authors: Lee, S.Y., Gill, C.M., Nicolau, D.P., Fang, F., Thomson, G.

Journal: Journal of Antimicrobial Chemotherapy

Year: 2023